Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Krillase is a standardized purified extract of proteolytic enzymes, specifically a synergistic combination of endo- and exopeptidases isolated from Antarctic krill (Euphausia superba). It is characterized by broad proteolytic activity over a wide temperature range, enabling efficient breakdown of proteins even at low temperatures. Krillase has been tested in chewing gum formulations for human dental hygiene, where it disrupts bacterial biofilm and adhesive proteins of oral bacteria, leading to reduced plaque formation and gingivitis. It is also being developed for wound debridement, chronic wound care, and veterinary dental hygiene in pets. Its key mechanism is the enzymatic degradation of protein biofilms and tissue debris, supporting oral and wound care. As of the current date, Krillase is classified as a Class III medical device in Europe for chronic wound treatment, but is not yet approved for use in the US[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Krillase.